These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27581118)

  • 1. The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements : Current Debate.
    Toumi M; Jarosławski S; Sawada T; Kornfeld Å
    Appl Health Econ Health Policy; 2017 Feb; 15(1):5-11. PubMed ID: 27581118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managed Entry Agreements: Policy Analysis From the European Perspective.
    Dabbous M; Chachoua L; Caban A; Toumi M
    Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts.
    Kannarkat JT; Good CB; Kelly E; Parekh N
    J Manag Care Spec Pharm; 2020 Jan; 26(1):63-66. PubMed ID: 31880231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts.
    Jarosławski S; Toumi M
    BMC Health Serv Res; 2011 Oct; 11():259. PubMed ID: 21982545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
    Towse A; Garrison LP
    Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Product listing agreements (PLAs): a new tool for reaching Quebec's pharmaceutical policy objectives?
    Bourassa Forcier M; Noël F
    Healthc Policy; 2013 Aug; 9(1):65-75. PubMed ID: 23968675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions.
    Bognar K; Romley JA; Bae JP; Murray J; Chou JW; Lakdawalla DN
    J Health Econ; 2017 Jan; 51():1-12. PubMed ID: 27992772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure.
    Navarria A; Drago V; Gozzo L; Longo L; Mansueto S; Pignataro G; Drago F
    Value Health; 2015 Jan; 18(1):131-6. PubMed ID: 25595244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects.
    Garrison LP; Carlson JJ; Bajaj PS; Towse A; Neumann PJ; Sullivan SD; Westrich K; Dubois RW
    Am J Manag Care; 2015 Sep; 21(9):632-40. PubMed ID: 26618366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States.
    Brown JD; Sheer R; Pasquale M; Sudharshan L; Axelsen K; Subedi P; Wiederkehr D; Brownfield F; Kamal-Bahl S
    Value Health; 2018 Jan; 21(1):33-40. PubMed ID: 29304938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Funding breakthrough therapies: A systematic review and recommendation.
    Hanna E; Toumi M; Dussart C; Borissov B; Dabbous O; Badora K; Auquier P
    Health Policy; 2018 Mar; 122(3):217-229. PubMed ID: 29223847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel.
    Triki N; Ash N; Porath A; Birnbaum Y; Greenberg D; Hammerman A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):749-753. PubMed ID: 31825682
    [No Abstract]   [Full Text] [Related]  

  • 15. [Innovative medicines and market access agreements].
    Toumi M; Zard J; Duvillard R; Jommi C
    Ann Pharm Fr; 2013 Sep; 71(5):302-25. PubMed ID: 24075701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience.
    Dunlop WCN; Staufer A; Levy P; Edwards GJ
    Health Policy; 2018 May; 122(5):528-532. PubMed ID: 29567205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement.
    Neumann PJ; Chambers JD; Simon F; Meckley LM
    Health Aff (Millwood); 2011 Dec; 30(12):2329-37. PubMed ID: 22147861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits.
    Zaric GS; Xie B
    Value Health; 2009; 12(5):838-45. PubMed ID: 19490563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].
    Hammerman A; Greenberg D
    Harefuah; 2012 Jun; 151(6):364-7, 376. PubMed ID: 22991869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the status and views of managed entry agreements in Saudi Arabia: mixed-methods approach.
    Al-Omar HA; Alghannam HH; Aljuffali IA
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):837-845. PubMed ID: 32658625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.